medbioМедико-биологические проблемы жизнедеятельностиMedical and Biological Problems of Life Activity2074-2088Республиканский научно-практический центр радиационной медицины и экологии человека10.58708/2074-2088.2024-2(32)-23-28medbio-377Research ArticleОБЗОРЫ И ПРОБЛЕМНЫЕ СТАТЬИREVIEWS AND PROBLEM ARTICLESНовые подходы в диагностике и терапии множественной миеломы (обзор литературы)New approaches in the diagnosis and treatment of multiple myeloma (review)https://orcid.org/0000-0002-3488-6650КозичЖ. М.KozichZh. M.

Врач-гематолог

г. Гомель

jannakozi@rambler.ruhttps://orcid.org/0000-0001-7029-5500МартинковВ. Н.MartinkovV. N.

г. Гомель

martinkov@rcrm.byКлимковичН. Н.KlimkovichN. N.

г. Минск

det.hematology@mail.ruРуденковаТ. В.RudenkovaT. V.

г. Минск

t.rudenkova@mail.ruКостюкС. А.KostyukS. A.

г. Минск

jannakozi@rambler.ruСердюковаН. В.SerdyukovaN. V.

г. Минск

natserdukova@incloud.comГУ «РНПЦ радиационной медицины и экологии человека»BelarusИнститут повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»BelarusГУ «Минский НПЦ хирургии, трансплантологии и гематологии»Belarus202411092024022328Copyright © Козич Ж.М., Мартинков В.Н., Климкович Н.Н., Руденкова Т.В., Костюк С.А., Сердюкова Н.В., 20242024Козич Ж.М., Мартинков В.Н., Климкович Н.Н., Руденкова Т.В., Костюк С.А., Сердюкова Н.В.Kozich Z.M., Martinkov V.N., Klimkovich N.N., Rudenkova T.V., Kostyuk S.A., Serdyukova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medbio.ejournal.by/jour/article/view/377

Множественная миелома – злокачественное новообразование, вызванное неконтролируемой пролиферацией опухолевых плазматических клеток. С внедрением новых препаратов и методов лечения в последнее десятилетие увеличилась глубина ответа и общая выживаемость пациентов с ММ. Однако ММ остается неизлечимым заболеванием с развитием рецидивов или рефрактерности к лечению. Поэтому поиск факторов прогноза является постоянной темой изучения многих исследований. Благодаря применению современных технологий в диагностике появилась возможность уже на начальном этапе выявлять группу пациентов с высоким риском прогрессии. Это позволяет разрабатывать новые стратегии в лечении. В данном обзоре представлены новые достижения в диагностике и лечении ММ.

Multiple myeloma is a malignant neoplasm caused by the uncontrolled proliferation of tumor plasma cells. With the introduction of new drugs and treatments in the last decade, the response rate and overall survival rate of MM patients have increased. However, MM remains an incurable disease with relapses or refractoriness to treatment. Therefore, the search for prognostic factors is a constant topic of study in many researches. Due to the application of modern technologies in diagnostics, it has become possible to identify a group of patients at high risk at an early stage. This allows the development of new treatment strategies. This review presents new achievements in the diagnosis and treatment of MM.

множественная миеломапроточная цитометрияNGSCAR-T клеточная терапияmultiple myelomaflow cytometryNGSCAR-T cell therapyReferencesPalumbo, A. Multiple myeloma / A. Palumbo, K.N. Anderson // Engl J Med. – 2011. – Т. 1046. – P. 10.Palumbo, A. Multiple myeloma / A. Palumbo, K.N. Anderson // Engl J Med. – 2011. – Т. 1046. – P. 10.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells / E. Pérez-Persona [et al.] // Blood, The Journal of the American Society of Hematology. – 2007. – Т. 110. – №. 7. – P. 2586-2592.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells / E. Pérez-Persona [et al.] // Blood, The Journal of the American Society of Hematology. – 2007. – Т. 110. – №. 7. – P. 2586-2592.Durie, B.G.M. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival / B.G.M. Durie, S.E. Salmon // Cancer. – 1975. – Т. 36. – №. 3. – P. 842-854.Durie, B.G.M. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival / B.G.M. Durie, S.E. Salmon // Cancer. – 1975. – Т. 36. – №. 3. – P. 842-854.International staging system for multiple myeloma / P.R. Greipp [et al.] // Journal of clinical oncology. – 2005. – Т. 23. – №. 15. – P. 3412-3420.International staging system for multiple myeloma / P.R. Greipp [et al.] // Journal of clinical oncology. – 2005. – Т. 23. – №. 15. – P. 3412-3420.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma / S.V. Rajkumar [et al.] // The lancet oncology. – 2014. – Т. 15. – №. 12. – P. e538-e548.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma / S.V. Rajkumar [et al.] // The lancet oncology. – 2014. – Т. 15. – №. 12. – P. e538-e548.Rajkumar, S.V. Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management / S.V. Rajkumar // American journal of hematology. – 2016. – Т. 91. – №. 7. – P. 719-734.Rajkumar, S.V. Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management / S.V. Rajkumar // American journal of hematology. – 2016. – Т. 91. – №. 7. – P. 719-734.Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation / A.C. Rawstron [et al.] // Blood, The Journal of the American Society of Hematology. – 2002. – Т. 100. – №. 9. – P. 3095-3100.Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation / A.C. Rawstron [et al.] // Blood, The Journal of the American Society of Hematology. – 2002. – Т. 100. – №. 9. – P. 3095-3100.Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology / E. Cannizzo [et al.] //Cytometry Part B: Clinical Cytometry. – 2010. – Т. 78, №4. – P. 231-238.Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology / E. Cannizzo [et al.] //Cytometry Part B: Clinical Cytometry. – 2010. – Т. 78, №4. – P. 231-238.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders / A.C. Rawstron [et al.] // Haematologica. – 2008. – Т. 93, №3. – P. 431-438.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders / A.C. Rawstron [et al.] // Haematologica. – 2008. – Т. 93, №3. – P. 431-438.Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma / N. Puig [et al.] // Cancers. – 2021. – Т. 13, №19. – P. 4924.Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma / N. Puig [et al.] // Cancers. – 2021. – Т. 13, №19. – P. 4924.VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma / A. Broijl [et al.] // American Journal of Clinical Pathology. – 2022. – Т. 157, №4. – P. 494-497.VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma / A. Broijl [et al.] // American Journal of Clinical Pathology. – 2022. – Т. 157, №4. – P. 494-497.CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab / K.T. Soh [et al.] //Cytometry Part B: Clinical Cytometry. – 2021. – Т. 100, №4. – P. 497-508.CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab / K.T. Soh [et al.] //Cytometry Part B: Clinical Cytometry. – 2021. – Т. 100, №4. – P. 497-508.Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network / D.H. Bruinink [et al.] // Haematologica. – 2021. – Т. 106, №5. – P. 1496.Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network / D.H. Bruinink [et al.] // Haematologica. – 2021. – Т. 106, №5. – P. 1496.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma / J. Flores‐Montero [et al.] // Cytometry Part B: Clinical Cytometry. – 2016. – Т. 90, №1. – P. 61-72.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma / J. Flores‐Montero [et al.] // Cytometry Part B: Clinical Cytometry. – 2016. – Т. 90, №1. – P. 61-72.Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience / H. Avet-Loiseau [et al.] // Journal of clinical oncology. – 2013. – Т. 31, №22. – P. 2806.Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience / H. Avet-Loiseau [et al.] // Journal of clinical oncology. – 2013. – Т. 31, №22. – P. 2806.Hanamura, I. Multiple myeloma with highrisk cytogenetics and its treatment approach / I. Hanamura // International Journal of Hematology. – 2022. – Т. 115, №6. – P. 762-777.Hanamura, I. Multiple myeloma with highrisk cytogenetics and its treatment approach / I. Hanamura // International Journal of Hematology. – 2022. – Т. 115, №6. – P. 762-777.A. Dhabe, Role of Conventional Cytogenetics and FISH in the Laboratory Work Up of Plasma Cell Dyscrasias / A. Dhabe, S. Das, M. Parihar // Indian Journal of Medical and Paediatric Oncology. – 2023.A. Dhabe, Role of Conventional Cytogenetics and FISH in the Laboratory Work Up of Plasma Cell Dyscrasias / A. Dhabe, S. Das, M. Parihar // Indian Journal of Medical and Paediatric Oncology. – 2023.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma / S. Kumar [et al.] // The lancet oncology. – 2016. – Т. 17, №8. – P. e328-e346.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma / S. Kumar [et al.] // The lancet oncology. – 2016. – Т. 17, №8. – P. e328-e346.Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges / G. Riva [et al.] //Cancers. – 2021. – Т. 13, №18. – P. 4582.Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges / G. Riva [et al.] //Cancers. – 2021. – Т. 13, №18. – P. 4582.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma / J. Flores‐Montero [et al.] // Cytometry Part B: Clinical Cytometry. – 2016. – Т. 90, №1. – P. 61-72.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma / J. Flores‐Montero [et al.] // Cytometry Part B: Clinical Cytometry. – 2016. – Т. 90, №1. – P. 61-72.Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice /A. Gozzetti [et al.] //Journal of Personalized Medicine. – 2020. – Т. 10, №3. – P. 120.Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice /A. Gozzetti [et al.] //Journal of Personalized Medicine. – 2020. – Т. 10, №3. – P. 120.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation / B. Paiva [et al.] // Blood. – 2008. – Vol. 112(10). – P. 4017-4023. https://doi.org/10.1182/blood-2008-05-159624.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation / B. Paiva [et al.] // Blood. – 2008. – Vol. 112(10). – P. 4017-4023. https://doi.org/10.1182/blood-2008-05-159624.Reuter, J.A. High-throughput sequencing technologies / J.A. Reuter, D.V. Spacek, M.P. Snyder // Molecular cell. – 2015. – Т. 58, №4. – P. 586-597. doi: 10.1016/j.molcel.2015.05.004Reuter, J.A. High-throughput sequencing technologies / J.A. Reuter, D.V. Spacek, M.P. Snyder // Molecular cell. – 2015. – Т. 58, №4. – P. 586-597. doi: 10.1016/j.molcel.2015.05.004NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial / J.M. Rosa-Rosa [et al.] // Cancers. – 2022. – Т. 14, №20. – P. 5169. doi: 10.3390/cancers14205169NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial / J.M. Rosa-Rosa [et al.] // Cancers. – 2022. – Т. 14, №20. – P. 5169. doi: 10.3390/cancers14205169Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma / J. Xu [et al.] // Proceedings of the National Academy of Sciences. – 2019. – Т. 116, №19. – P. 9543-9551. doi: 10.1073/pnas.1819745116.Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma / J. Xu [et al.] // Proceedings of the National Academy of Sciences. – 2019. – Т. 116, №19. – P. 9543-9551. doi: 10.1073/pnas.1819745116.A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/ refractory multiple myeloma / D. Wang [et al.] // Blood, The Journal of the American Society of Hematology. – 2021. – Т. 137, №21. – P. 2890-2901. doi: 10.1182/blood.2020008936A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/ refractory multiple myeloma / D. Wang [et al.] // Blood, The Journal of the American Society of Hematology. – 2021. – Т. 137, №21. – P. 2890-2901. doi: 10.1182/blood.2020008936

The authors declare that there are no conflicts of interest present.